sc-ImmuCC: hierarchical annotation for immune cell types in single-cell RNA-seq.

hierarchical annotation immune cell identification immune cell signature sets scRNA-seq ssGSEA

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 16 05 2023
accepted: 03 07 2023
medline: 8 8 2023
pubmed: 7 8 2023
entrez: 7 8 2023
Statut: epublish

Résumé

Accurately identifying immune cell types in single-cell RNA-sequencing (scRNA-Seq) data is critical to uncovering immune responses in health or disease conditions. However, the high heterogeneity and sparsity of scRNA-Seq data, as well as the similarity in gene expression among immune cell types, poses a great challenge for accurate identification of immune cell types in scRNA-Seq data. Here, we developed a tool named sc-ImmuCC for hierarchical annotation of immune cell types from scRNA-Seq data, based on the optimized gene sets and ssGSEA algorithm. sc-ImmuCC simulates the natural differentiation of immune cells, and the hierarchical annotation includes three layers, which can annotate nine major immune cell types and 29 cell subtypes. The test results showed its stable performance and strong consistency among different tissue datasets with average accuracy of 71-90%. In addition, the optimized gene sets and hierarchical annotation strategy could be applied to other methods to improve their annotation accuracy and the spectrum of annotated cell types and subtypes. We also applied sc-ImmuCC to a dataset composed of COVID-19, influenza, and healthy donors, and found that the proportion of monocytes in patients with COVID-19 and influenza was significantly higher than that in healthy people. The easy-to-use sc-ImmuCC tool provides a good way to comprehensively annotate immune cell types from scRNA-Seq data, and will also help study the immune mechanism underlying physiological and pathological conditions.

Identifiants

pubmed: 37545533
doi: 10.3389/fimmu.2023.1223471
pmc: PMC10399579
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1223471

Informations de copyright

Copyright © 2023 Jiang, Chen, Han, Shang and Wu.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Comput Struct Biotechnol J. 2021 Oct 20;19:5874-5887
pubmed: 34815832
Sci Rep. 2017 Jan 13;7:40508
pubmed: 28084418
Cardiovasc Res. 2017 Jul 1;113(9):1009-1023
pubmed: 28838042
Brief Bioinform. 2021 Sep 2;22(5):
pubmed: 33681983
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Nat Protoc. 2018 Apr;13(4):599-604
pubmed: 29494575
Nat Rev Genet. 2019 May;20(5):273-282
pubmed: 30617341
Front Immunol. 2018 Jun 05;9:1286
pubmed: 29922297
J Cancer. 2013;4(1):84-95
pubmed: 23386907
Nat Methods. 2020 Dec;17(12):1200-1206
pubmed: 33077966
J Vis Exp. 2012 Jun 16;(64):e3952
pubmed: 22733225
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651212
Front Genet. 2020 May 12;11:490
pubmed: 32477414
Brief Bioinform. 2021 Sep 2;22(5):
pubmed: 33401306
PLoS One. 2016 Mar 03;11(3):e0150606
pubmed: 26938654
Innovation (Camb). 2022 Sep 13;3(5):100289
pubmed: 35879967
PLoS One. 2016 Jun 16;11(6):e0156660
pubmed: 27310868
Sci Transl Med. 2021 Jan 27;13(578):
pubmed: 33431511
Cancer Immunol Immunother. 2018 Jul;67(7):1031-1040
pubmed: 29541787
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Genome Biol. 2019 Dec 12;20(1):264
pubmed: 31829268
Genome Biol. 2004;5(10):R80
pubmed: 15461798
iScience. 2020 Mar 27;23(3):100882
pubmed: 32062421
Nat Protoc. 2021 Jun;16(6):2749-2764
pubmed: 34031612
Clin Transl Med. 2022 Mar;12(3):e694
pubmed: 35352511
Nat Methods. 2019 Oct;16(10):983-986
pubmed: 31501545
Br J Cancer. 2013 Mar 5;108(4):914-23
pubmed: 23385730
Exp Mol Med. 2018 Aug 7;50(8):1-14
pubmed: 30089861
Nat Biotechnol. 2022 Jan;40(1):30-41
pubmed: 34931002
Genes (Basel). 2019 Jul 12;10(7):
pubmed: 31336988
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Nat Methods. 2009 May;6(5):377-82
pubmed: 19349980
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508

Auteurs

Ying Jiang (Y)

State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.

Ziyi Chen (Z)

State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.

Na Han (N)

State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.

Jingzhe Shang (J)

State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.

Aiping Wu (A)

State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH